<DOC>
	<DOCNO>NCT01464099</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial evaluate clinical performance two formulation insulin aspart ( NovoLog® ) subject type 1 diabetes .</brief_summary>
	<brief_title>Bioequivalence Two NovoLog® Formulations Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Subjects type 1 diabetes treat insulin least 12 month BMI ( Body Mass Index ) 18.029.0 kg/m^2 Negative fasting Cpeptide ( equal 0.6 ng/mL ) HbA1c ( glycosylated haemoglobin A1c ) equal 10.0 % Current treatment insulin equal 1.2 U/kg/day Subject good health base medical history , physical examination routine laboratory data Any known/suspected allergy trial medication similar products/devices A subject proliferative retinopathy maculopathy , and/or severe neuropathy , particular autonomic neuropathy , judge Investigator Clinically significant active disease kind Recurrent major hypoglycemia hypoglycemic unawareness , judge Investigator Blood donation ( 500 mL ) within previous 9 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>